|Description||E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2, which enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.|
|Synonyms||E7449; E 7449; E-7449; 2X-121; 2X 121; 2X121;|
E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2, which enhances the efficacy of radiotherapy and chemotherapy and has poten...
Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a ...
Niraparib is an inhibitor of PARP, which was approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube o...
Rucaparib camsylate is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which work in DNA repair process. It was approved for the treatment of ovari...
MK-4827 HCl is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. It has a great activity in cancer cells with mutant BRCA-1 and BRCA-2, >330-fold...
BYK 49187 is a non-selective PARP inhibitor (pIC50 = 8.36 and 7.50 for cell-free recombinant PARP-1 and murine PARP-2, respectively).
G007-LK is a potent, "rule of 5" compliant and a metabolically stable TNKS1/2 inhibitor. G007-LK displayed high selectivity toward tankyrases 1 and 2 with bioch...
DR 2313 has been found to be a PARP-1/PARP-2 inhibitor and could exhibit neuroprotective avtivities as well as reduce cortical infarct volume in focal ischemia.